PatientsVille.com Logo


Pulmonary Hypertension Medical Research Studies

Up-to-date List of Pulmonary Hypertension Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Pulmonary Hypertension Medical Research Studies

Rank Status Study
1 Recruiting Trans-pulmonary Biomarkers in PULMONARY HYPERTENSION
Condition: Pulmonary Hypertension
Outcome Measures: Differences in PULMONARY HYPERTENSION biomarkers in patients evaluated for PULMONARY HYPERTENSION;   Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR);   Vasodilator-induced changes in PULMONARY HYPERTENSION biomarkers
2 Recruiting Phase-II Study of the Use of PulmoBind for Molecular Imaging of PULMONARY HYPERTENSION
Condition: Pulmonary Hypertension
Intervention: Drug: PulmoBind
Outcome Measures: To determine the absence of allergic reaction after repeated exposures to PulmoBind in healthy participants;   To determine the safety of PulmoBind in participants diagnosed with PULMONARY HYPERTENSION.;   To determine the capacity of PulmoBind lung scan for the detection of abnormal pulmonary circulation associated with PULMONARY HYPERTENSION.;   To determine the intra-subject variability for quantification of PulmoBind lung uptake in control participants;   Determine the capacity of PulmoBind lung scan to diagnose pulmonary perfusion defects in participants with chronic thromboembolic PULMONARY HYPERTENSION.;   To correlate lung PulmoBind scan results with parameters of the severity of PULMONARY HYPERTENSION: 6 minutes walking distance, New York Heart Association functional class, pulmonary artery pressure measured by echo, pulmonary artery pressure measured by
3 Recruiting A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent PULMONARY HYPERTENSION Of The Newborn
Condition: PULMONARY HYPERTENSION, Familial Persistent, of the Newborn
Interventions: Drug: placebo;   Drug: iv sildenafil
Outcome Measures: Time on inhaled nitric oxide treatment after initiation of iv study drug;   Treatment failure rate, defined as need for additional treatment targeting persistent PULMONARY HYPERTENSION of the newborn.;   Time to final weaning of mechanical ventilation for persistent PULMONARY HYPERTENSION of the newborn;   Time from initiation of study drug to treatment failure;   Change in oxygenation parameters at 6, 12, and 24 hours from baseline;   Sildenafil plasma concentrations and corresponding PK parameters;   Safety parameters: incidence and severity of adverse events and abnormal laboratory parameters
4 Unknown  Ambrisentan (Letairis) for Sarcoidosis Associated PULMONARY HYPERTENSION
Conditions: Sarcoidosis;   Pulmonary Hypertension
Intervention: Drug: Ambrisentan
Outcome Measure: Change in 6 minute walk distance.
5 Recruiting A Case Control Study of the Prevalence of PULMONARY HYPERTENSION in Patients With Myeloproliferative Diseases.
Conditions: Myeloproliferative Disease;   Pulmonary Hypertension
Intervention: Other: myeloproliferative disease
Outcome Measures: pulmonary hypertension;   St George Respiratory Questionnaire
6 Recruiting Inhaled Iloprost in the Treatment of Patients With PULMONARY HYPERTENSION up to 4 Years
Condition: Pulmonary Hypertension
Intervention: Drug: Ventavis inhaled (Iloprost, BAYQ6256)
Outcome Measures: 6 Minutes walking distance (change in meters);   Adverse events, weight, vital findings;   6 Minutes walking distance (% change);   New York Heart Association Functional Class;   Change in drug dosage or frequency, need for PAH specific drug combination, need for drug change;   Pulmonary hypertension related hospitalization;   Heart and/or lung transplantation, mortality
7 Recruiting Secondary PULMONARY HYPERTENSION in Adults With Sickle Cell Anemia
Conditions: Pulmonary Hypertension;   Sickle Cell Anemia;   Sickle Cell Disease
Outcome Measures: To determine the prevalence and prognosis of secondary PULMONARY HYPERTENSION in adult patients with sickle cell anemia.;   To determine whether genetic polymorphisms in candidate genes contribute to its development or response to treatment.
8 Recruiting Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on PULMONARY HYPERTENSION
Conditions: Pulmonary Hypertension;   Pulmonary Arterial Hypertension;   Cardiovascular Diseases;   Lung Diseases;   Tanshinone IIA Sulfonate
Interventions: Drug: 20 mg sildenafil  citrate by mouth;   Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
Outcome Measures: mPAP by right heart catheterization;   WHO functional class of PULMONARY HYPERTENSION(PH);   Borg dyspnea score;   Minnesota living with heart failure questionnaire;   6-minute walk distance (6MWD);   Pulmonary vascular resistance(PVR) measured by right heart catheterization
9 Recruiting Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Ventricular Function in Severe PULMONARY HYPERTENSION
Condition: Pulmonary Hypertension
Intervention: Other: respiratory and exercise therapy
Outcome Measures: Improvement of peak O2 uptake (VO2peak) under stress;   Changes in hemodynamics at rest and during exercise
10 Recruiting Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary PULMONARY HYPERTENSION Due to Left Ventricular Dysfunction
Conditions: Pre-capillary Pulmonary Hypertension;   Post-capillary Pulmonary Hypertension;   Left Ventricular Dysfunction
Interventions: Drug: Macitentan;   Drug: Placebo
Outcome Measures: To evaluate the safety and tolerability of macitentan 10 mg in subjects with CpcPH;   To evaluate the efficacy of macitentan 10 mg in subjects with CpcPH
11 Recruiting Tadalafil for PULMONARY HYPERTENSION Due to Chronic Lung Disease
Conditions: Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Tadalafil;   Drug: placebo
Outcome Measures: Change in 6 minute walk test;   Maximum volume of oxygen extraction on exercise testing;   Pulmonary vascular resistance;   Mean pulmonary artery pressure;   Tricuspid annular plane excursion (TAPSE);   Dyspnea and health related quality of life (HRQL);   N-type brain natriuretic peptide (BNP) concentration;   Resting Hypoxemia;   Exercise-induced hypoxemia
12 Unknown  PULMONARY HYPERTENSION, Quality of Life and Psychosocial Factors
Condition: Pulmonary Hypertension
Intervention: Behavioral: Evaluation of quality of life
Outcome Measures: Descriptive analysis of psychological characteristics on PAH patients;   Psychological characteristics impact on Quality of life;   Association between disease and Quality of life evolution;   Variability of Quality of life parameters over severity class changes and follow-up
13 Recruiting Noninvasive Cardiac Output Measurements in Patients With PULMONARY HYPERTENSION Undergoing Right Heart Catheterization With Acute Vasodilator Testing
Condition: Pulmonary Hypertension
Outcome Measure: To determine the accuracy of a noninvasive method of measuring cardiac output as compared to the standard invasive approach using thermodilution in patients with PULMONARY HYPERTENSION
14 Recruiting Database for Clinical and Anamnestic Data in PULMONARY HYPERTENSION
Condition: Pulmonary Hypertension
Outcome Measure: Collecting data in a PH patient database
15 Recruiting Targeting the Right Ventricle in PULMONARY HYPERTENSION
Condition: Pulmonary Hypertension
Interventions: Drug: Ranolazine;   Drug: Placebo
Outcome Measures: Number and percentage of subjects with high risk profile at end of the study;   Glucose and lipid metabolites;   Changes from baseline in glucose and lipid metabolism
16 Recruiting Registry for PULMONARY HYPERTENSION in China
Conditions: Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension;   Death
Outcome Measure: Survival
17 Unknown  Trial of Iloprost in PULMONARY HYPERTENSION Secondary to Pulmonary Fibrosis
Conditions: Pulmonary Fibrosis;   Pulmonary Hypertension
Intervention: Drug: Iloprost inhalation
Outcome Measures: Safety;   Pulmonary arterial pressure;   Exercise capacity (6 minute walking test);   6 minute walking test: Min. oxygen saturation.;   NYHA class,;   Quality of life (St. George Respiratory questionnaires);   Pulmonary vascular resistance, cardiac output.;   Increment of pulmonary arterial pressure after the exercise;   6) Pulmonary function test
18 Recruiting Treatment of PULMONARY HYPERTENSION Associated COPD With Inhaled Treprostinil-1
Conditions: Pulmonary Hypertension;   COPD
Intervention: Drug: Inhaled Treprostinil Therapy
Outcome Measures: To assess the safety of Tyvaso ® as assessed by changes or stability of acute oxygenation (pulse oximetry) and spirometry (FEV1).;   New York Heart Association (NYHA) functional class;   Six minute walk distance;   Clinical Worsening;   Peripheral Blood Mononuclear Cells (PBMC) phagocytic index (PI) and PBMC gene expression;   St. George's Chronic Obstructive Pulmonary Disease (COPD) questionnaire
19 Recruiting Registry for PULMONARY HYPERTENSION Due to Left Heart Disease in China
Condition: Pulmonary Hypertension Due to Left Heart Disease
Intervention: Other: Routine therapy
Outcome Measure: All cause death
20 Recruiting Investigation of Dysynchrony in Patients With PULMONARY HYPERTENSION
Condition: Pulmonary Hypertension
Intervention: Procedure: Catheterization Pacing
Outcome Measure: Electrical or Mechanical Dysynchrony

These studies may lead to new treatments and are adding insight into Pulmonary Hypertension etiology and treatment.

A major focus of Pulmonary Hypertension research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Pulmonary Hypertension